IMEIK(300896):4Q25 REVENUE DECLINE NARROWS QOQ PAY ATTENTION TO NEW PRODUCTS AND INTERNATIONALIZATION PROCESS IN 2026

Apr 16 00:00

Aimeike (300896): Revenue decline narrowed quarter-on-quarter in Q4 2025; focus on new product launches and international expansion in 2026.

The core view is that the company's revenue in 2025 will be RMB 2.45 billion, a year-on-year decrease of 18.9%, remaining under pressure. This is mainly due to weak consumer demand in the medical aesthetics sector and intensified market competition faced by products such as HiBody and regenerative lines. In Q4 2025, revenue decreased by 9% year-on-year.

CSC Financial Co., Ltd.Apr 15 16:12

Shenwan Hongyuan: Cosmetics and medical aesthetics brands achieve steady growth, while the manufacturing sector shows marginal improvement.

It is anticipated that cost-effective light medical aesthetic services will become the main driver for institutional expansion in the future.

Zhitong FinanceApr 14 15:41

Aimeike (300896): Intensified competition for older products leads to revenue decline; increased expenses during the new product launch phase weigh on performance. Focus on the inflection point for new product sales growth.

The company disclosed its 25-year annual report, with performance falling below expectations. In the 25th year, revenue reached 2.453 billion yuan, a decrease of 18.94% year-on-year, while net profit attributable to shareholders was 1.291 billion yuan, representing a decline of 34.05%. Non-recurring net profit attributable to shareholders amounted to 1.099 billion yuan, reflecting a reduction of 4%.

Founder SecuritiesApr 4 00:00

Aimeike hit a historic low.

On April 3, Glodon News reported that Aimeike (300896.SZ) fell by 0.87%, closing at RMB 113.980, hitting a new historical low in share price, with a total market capitalization of RMB 34.489 billion.

Gelonghui FinanceApr 3 09:41

Nomura Starts Imeik Technology Development at Neutral With 123.90 Yuan Price Target

MT NewswiresApr 1 19:16 · Ratings